Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1974 1
1975 1
1976 2
1977 3
1978 3
1979 7
1980 1
1981 7
1982 2
1983 4
1984 4
1985 3
1986 3
1987 3
1989 3
1991 2
1993 1
1994 1
1996 2
1997 2
1998 3
1999 1
2000 3
2001 1
2003 3
2004 1
2005 3
2006 3
2007 1
2008 3
2009 2
2010 3
2011 5
2012 6
2013 2
2014 3
2015 6
2016 2
2017 4
2018 5
2019 6
2020 5
2021 7
2022 7
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "GCGR-related hyperglucagonemia"
Page 1
100 years of glucagon and 100 more.
Wewer Albrechtsen NJ, Holst JJ, Cherrington AD, Finan B, Gluud LL, Dean ED, Campbell JE, Bloom SR, Tan TM, Knop FK, Müller TD. Wewer Albrechtsen NJ, et al. Diabetologia. 2023 Aug;66(8):1378-1394. doi: 10.1007/s00125-023-05947-y. Epub 2023 Jun 27. Diabetologia. 2023. PMID: 37367959 Review.
In individuals with diabetes and fatty liver diseases, glucagon's hepatic actions may be partly impaired resulting in elevated levels of glucagonotropic amino acids, dyslipidaemia and hyperglucagonaemia, reflecting a new, so far largely unexplored pathophysiological phenom …
In individuals with diabetes and fatty liver diseases, glucagon's hepatic actions may be partly impaired resulting in elevated levels of glu …
The biology of glucagon and the consequences of hyperglucagonemia.
Wewer Albrechtsen NJ, Kuhre RE, Pedersen J, Knop FK, Holst JJ. Wewer Albrechtsen NJ, et al. Biomark Med. 2016 Nov;10(11):1141-1151. doi: 10.2217/bmm-2016-0090. Epub 2016 Sep 9. Biomark Med. 2016. PMID: 27611762 Review.
Glucagon increases blood glucose levels through gluconeogenesis and glycogenolysis. Elevated plasma concentrations of glucagon, hyperglucagonemia, may contribute to diabetes. However, hyperglucagonemia is also observed in other clinical conditions than diabet …
Glucagon increases blood glucose levels through gluconeogenesis and glycogenolysis. Elevated plasma concentrations of glucagon, hypergluc …
A Primary Role for α-Cells as Amino Acid Sensors.
Dean ED. Dean ED. Diabetes. 2020 Apr;69(4):542-549. doi: 10.2337/dbi19-0021. Epub 2019 Oct 25. Diabetes. 2020. PMID: 31653720 Free PMC article. Review.
Glucagon signaling increases hepatic glucose output, and hyperglucagonemia is partly responsible for the hyperglycemia in diabetes, making glucagon an attractive target for therapeutic intervention. ...New evidence suggests that dysfunction of the axis in humans may result …
Glucagon signaling increases hepatic glucose output, and hyperglucagonemia is partly responsible for the hyperglycemia in diabetes, m …
Hyperglucagonemia in Pediatric Adiposity Associates With Cardiometabolic Risk Factors but Not Hyperglycemia.
Stinson SE, Jonsson AE, de Retana Alzola IF, Lund MAV, Frithioff-Bøjsøe C, Aas Holm L, Fonvig CE, Pedersen O, Ängquist L, Sørensen TIA, Holst JJ, Christiansen M, Holm JC, Hartmann B, Hansen T. Stinson SE, et al. J Clin Endocrinol Metab. 2022 May 17;107(6):1569-1576. doi: 10.1210/clinem/dgac108. J Clin Endocrinol Metab. 2022. PMID: 35213713 Free PMC article.
CONTEXT: In adults, hyperglucagonemia is associated with type 2 diabetes, impaired glucose tolerance, and obesity. ...CONCLUSION: Compared with normal weight peers, children and adolescents with overweight/obesity had elevated concentrations of fasting glucagon, which corr …
CONTEXT: In adults, hyperglucagonemia is associated with type 2 diabetes, impaired glucose tolerance, and obesity. ...CONCLUSION: Com …
Prostaglandins and the alpha-cell.
Giugliano D, Torella R, D'Onofrio F. Giugliano D, et al. Prostaglandins Med. 1981 Mar;6(3):283-97. doi: 10.1016/0161-4630(81)90152-x. Prostaglandins Med. 1981. PMID: 7012876 Review.
While in the rat this response seems independent of the adrenergic nervous system, in man the hyperglucagonemia induced by PGE1 is easily suppressed by propranolol, suggesting an interaction between the prostaglandin and the beta-receptors of the alpha-cell. ...In insulin- …
While in the rat this response seems independent of the adrenergic nervous system, in man the hyperglucagonemia induced by PGE1 is ea …
Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes.
Wewer Albrechtsen NJ, Møller A, Martinussen C, Gluud LL, Rashu EB, Richter MM, Plomgaard P, Goetze JP, Kjeldsen S, Hansen LH, Gustafsson F, Deacon CF, Holst JJ, Madsbad S, Bojsen-Møller KN. Wewer Albrechtsen NJ, et al. Diabetes Obes Metab. 2022 Oct;24(10):2017-2026. doi: 10.1111/dom.14789. Epub 2022 Jul 21. Diabetes Obes Metab. 2022. PMID: 35676803 Free PMC article. Clinical Trial.
CONCLUSIONS: The glucose-lowering effects of long-term sacubitril/valsartan treatment reported in patients with heart failure and type 2 diabetes may not depend on changes in entero-pancreatic hormones. Neprilysin inhibition results in hyperglucagonaemia and this may expla …
CONCLUSIONS: The glucose-lowering effects of long-term sacubitril/valsartan treatment reported in patients with heart failure and type 2 dia …
Lack of glucagon receptor signaling and its implications beyond glucose homeostasis.
Charron MJ, Vuguin PM. Charron MJ, et al. J Endocrinol. 2015 Mar;224(3):R123-30. doi: 10.1530/JOE-14-0614. Epub 2015 Jan 7. J Endocrinol. 2015. PMID: 25568163 Review.
Lack of Gcgr signaling has been associated with: i) hypoglycemic pregnancies, altered placentation, poor fetal growth, and increased fetal-neonatal death; ii) pancreatic glucagon cell hyperplasia and hyperglucagonemia; iii) altered body composition, energy state, and prote …
Lack of Gcgr signaling has been associated with: i) hypoglycemic pregnancies, altered placentation, poor fetal growth, and increased fetal-n …
Determinants of hyperglucagonemia in pediatric non-alcoholic fatty liver disease.
Maruszczak K, Radzikowski K, Schütz S, Mangge H, Bergsten P, Forslund A, Manell H, Pixner T, Ahlström H, Kullberg J, Mörwald K, Weghuber D. Maruszczak K, et al. Front Endocrinol (Lausanne). 2022 Sep 5;13:1004128. doi: 10.3389/fendo.2022.1004128. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36133310 Free PMC article.
Risk factors included hypercaloric diet, obesity, insulin resistance and genetics. Hyperglucagonemia appears to be a pathophysiological consequence of hepatic steatosis, thus, the hypothesis of the study is that hepatic fat accumulation leads to increased insulin resistanc …
Risk factors included hypercaloric diet, obesity, insulin resistance and genetics. Hyperglucagonemia appears to be a pathophysiologic …
EJE PRIZE 2018: A gut feeling about glucagon.
Knop FK. Knop FK. Eur J Endocrinol. 2018 Jun;178(6):R267-R280. doi: 10.1530/EJE-18-0197. Epub 2018 Apr 20. Eur J Endocrinol. 2018. PMID: 29678923 Review.
Since we observed that the well-known hyperglucagonaemic response to oral glucose in patients with type 2 diabetes is exchanged by normal suppression of plasma glucagon levels following isoglycaemic intravenous glucose administration in these patients, we have been focusin …
Since we observed that the well-known hyperglucagonaemic response to oral glucose in patients with type 2 diabetes is exchanged by no …
Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.
Pettus J, Boeder SC, Christiansen MP, Denham DS, Bailey TS, Akturk HK, Klaff LJ, Rosenstock J, Cheng MHM, Bode BW, Bautista ED, Xu R, Yan H, Thai D, Garg SK, Klein S. Pettus J, et al. Nat Med. 2022 Oct;28(10):2092-2099. doi: 10.1038/s41591-022-02011-x. Epub 2022 Oct 3. Nat Med. 2022. PMID: 36192552 Free PMC article. Clinical Trial.
Hyperglucagonemia contributes to hyperglycemia in patients with type 1 diabetes (T1D); however, novel therapeutics that block glucagon action could improve glycemic control. ...At week 13, the placebo-corrected reduction in HbA1c percentage was -0.53 (95% CI -0.89 to -0.17 …
Hyperglucagonemia contributes to hyperglycemia in patients with type 1 diabetes (T1D); however, novel therapeutics that block glucago …
132 results